Patent 11179378 was granted and assigned to The Children'S Hospital Of Philadelphia on November, 2021 by the United States Patent and Trademark Office.
Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.